Prediction of PD-L1 expression in NSCLC patients using PET/CT radiomics and prognostic modelling for immunotherapy in PD-L1-positive NSCLC patients.

Journal: Clinical radiology
Published Date: Apr 2, 2025

Abstract

AIM: To develop a positron emission tomography/computed tomography (PET/CT)-based radiomics model for predicting programmed cell death ligand 1 (PD-L1) expression in non-small cell lung cancer (NSCLC) patients and estimating progression-free survival (PFS) and overall survival (OS) in PD-L1-positive patients undergoing first-line immunotherapy.

Authors

  • M Peng
    PET-CT/MRI Department, Harbin Medical University Cancer Hospital, No.150 Haping Road, Harbin, Heilongjiang, China. Electronic address: pmy18846410991@163.com.
  • M Wang
  • X Yang
    Department of Urology, Affiliated Hospital of Qingdao University, Qingdao, China.
  • Y Wang
    1 School of Public Health, Capital Medical University, Beijing, China.
  • L Xie
    From the Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
  • W An
    Department of Urology, Harbin Medical University Cancer Hospital, Harbin, China. Electronic address: awx1999@163.com.
  • F Ge
    PET-CT/MRI Department, Harbin Medical University Cancer Hospital, No.150 Haping Road, Harbin, Heilongjiang, China. Electronic address: gf7521946552022@163.com.
  • C Yang
  • K Wang
    PET-CT/MRI Department, Harbin Medical University Cancer Hospital, No.150 Haping Road, Harbin, Heilongjiang, China. Electronic address: wangkezheng9954001@163.com.

Keywords

External Resources

Popular Topics
Recent Journals